The aim of this clinical research project is to evaluate the use of the recombinant human
activated factor VII (rhFVIIa), given as a salvage therapy, in women with a dramatic
postpartum hemorrhage still ongoing after all the currently available medical and surgical
treatments. We are going to compare its early use, before elective surgery or arterial
embolization, to its late use, after embolization or surgery, before salvage hysterectomy.
Phase:
Phase 4
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Collaborators:
Assistance Publique - Hôpitaux de Paris Centre Hospitalier Universitaire de Nice University Hospital, Geneva University Hospital, Lille University Hospital, Montpellier